Levetiracetam Tablet, Film Coated
Product Images NDC 64980-605

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 64980-605). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam-1000mg-60ct (Levetiracetam 1000mg 60ct)

Levetiracetam Tablets, USP 1000 mg film-coated tablets packaging label from Rising Pharma Holdings, Inc. The label includes directions for pharmacists, storage instructions at 20° to 25°C, and states the product is made in India. The package contains 60 tablets and features an NDC barcode and a reminder for pharmacists to provide the Medication Guide.*

FDA Label Image

Levetiracetam-250mg-120ct (Levetiracetam 250mg 120ct)

Levetiracetam Tablets USP 250 mg, film-coated oral tablets, packaged by Rising Pharma Holdings, Inc. The label states 120 tablets per container with a requirement that each patient receives the accompanying Medication Guide. It includes storage instructions, manufacturer details, and a barcode.*

FDA Label Image

Levetiracetam-500mg-120ct (Levetiracetam 500mg 120ct)

Drug label text panel for Levetiracetam Tablets USP, 500 mg, highlighting pharmacist instructions including dispensing in light-resistant containers, storage conditions at 20° to 25°C, and requiring a Medication Guide. The panel notes a package size of 120 tablets, Rx only, manufactured for Rising Pharma Holdings, Inc., with a barcode on the right side.*

FDA Label Image

Levetiracetam-750mg-120ct (Levetiracetam 750mg 120ct)

Levetiracetam Tablets, USP 750 mg film-coated oral tablets in a carton labeled for 120 tablets. The label includes dosing and storage instructions, pharmacist dispensing guidelines, and a link for the medication guide. It is manufactured for Rising Pharma Holdings, Inc., with an NDC of 64980-606-12. The product is marked as prescription only (Rx only) and made in India.*

FDA Label Image

Levetiracetam-fig1 (Levetiracetam Fig1)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients responding to placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows responder rates of 7.4% for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with a note indicating statistical significance versus placebo.*

FDA Label Image

Levetiracetam-fig2 (Levetiracetam Fig2)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' displaying the percentage of patients achieving this response. The chart compares three groups: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). Asterisks indicate statistically significant differences from placebo.*

FDA Label Image

Levetiracetam-fig3 (Levetiracetam Fig3)

Bar chart showing responder rates with at least 50% reduction from baseline in Study 3. The chart compares placebo (14.4% response, N=104) to Levetiracetam 3000 mg/day (39.4% response, N=180). An asterisk indicates the Levetiracetam group results are statistically significant versus placebo.*

FDA Label Image

Levetiracetam-fig4 (Levetiracetam Fig4)

A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients responding to placebo and Levetiracetam treatments. The placebo group (N=97) shows a response rate of 19.6%, while the Levetiracetam group (N=101) shows a higher response rate of 44.6%, marked as statistically significant versus placebo.*

FDA Label Image

Levetiracetam-fig5 (Levetiracetam Fig5)

Bar chart showing responder rates (≥ 50% reduction from baseline) in patients aged 1 month to under 4 years in Study 5. The chart compares placebo with Levetiracetam, with Levetiracetam demonstrating a higher responder rate (43.1%) than placebo (19.6%). The difference is marked as statistically significant.*

FDA Label Image

Levetiracetam-fig6 (Levetiracetam Fig6)

Bar graph illustrating responder rates (≥50% reduction from baseline) in PGTC seizure frequency per week from Study 7. The graph compares placebo (45.2%) and Levetiracetam (72.2%), showing a higher responder rate for Levetiracetam. The y-axis represents the percentage of patients, the x-axis has placebo and Levetiracetam groups.*

FDA Label Image

Levetiracetam-str (Levetiracetam Str)

Chemical structure of Levetiracetam showing a pyrrolidone ring attached to an amide and an ethyl group, representing the molecular arrangement of the active ingredient Levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.